Does rosilitazone adversely affect bone formation and bone mineral density in postmenopasal women?

被引：5

作者：

Schwartz, Ann V.

Cummings, Steven R.

机构：

[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA

[2] Calif Pacific Med Ctr, Geraldine Brush Canc Res Inst, San Francisco, CA 94115 USA

来源：

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2007年 / 3卷 / 09期

关键词：

bone formation; bone resorption; peroxisome proliferator-activated receptor gamma; rosiglitazone;

D O I：

10.1038/ncpendmet0562

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：622 / 623

页数：2

共 5 条

[1] INFLUENCE OF FAT ON BONE MEASUREMENTS WITH DUAL-ENERGY ABSORPTIOMETRY [J].

HANGARTNER, TN ;

JOHNSTON, CC .

BONE AND MINERAL, 1990, 9 (01) :71-81

[2] Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [J].

Kahn, Steven E. ;

Haffner, Steven M. ;

Heise, Mark A. ;

Herman, William H. ;

Holman, Rury R. ;

Jones, Nigel P. ;

Kravitz, Barbara G. ;

Lachin, John M. ;

O'Neill, M. Colleen ;

Zinman, Bernard ;

Viberti, Giancarlo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2427-2443

[3] Bone is a target for the antidiabetic compound rosiglitazone [J].

Rzonca, SO ;

Suva, LJ ;

Gaddy, D ;

Montague, DC ;

Lecka-Czernik, B .

ENDOCRINOLOGY, 2004, 145 (01) :401-406

[4] Thiazolidinedione use and bone loss in older diabetic adults [J].

Schwartz, Ann V. ;

Sellmeyer, Deborah E. ;

Vittinghoff, Eric ;

Palermo, Lisa ;

Lecka-Czernik, Beata ;

Feingold, Kenneth R. ;

Strotmeyer, Elsa S. ;

Resnick, Helaine E. ;

Carbone, Laura ;

Beamer, Brock A. ;

Park, Seok Won ;

Lane, Nancy E. ;

Harris, Tamara B. ;

Cummings, Steven R. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3349-3354

[5]

TAKEDA PHARM LETT HE

← 1 →